Evandro F. Fang, Ph.D.

Associate Professor, Molecular Gerontology, University of Oslo (UiO), Norway

Evandro F. Fang is an Associate Professor of Molecular Gerontology at the University of Oslo (UiO), Norway, and his group are working on the molecular mechanisms of human ageing and age-predisposed neurodegeneration (https://evandrofanglab.com/). More specifically, the Fang laboratory is focusing on the molecular mechanisms behind how cells clear their damaged and aged mitochondria, a process termed “mitophagy”, as well as the roles of the NAD+-mitophagy/autophagy axis in healthy ageing and AD inhibition. NAD+ is a fundamental molecule in life and health and decreases in ageing and AD. Dr Fang is fascinated with and actively engaged in moving his laboratory findings to translational applications and is involved in 5+ NAD+-based clinical trials, with the overarching goal of establishing novel and safe biological approaches to promote longer and healthier human lives.

After finishing his Ph.D. at the Chinese Universtiy of Hong Kong, he had a 6-year postdoc training with Prof. Vilhelm Bohr on molecular gerontology at the National Institute on Ageing, Baltimore. He opened his lab in Oslo in the fall of 2017. He has published over 100 papers in international peer-reviewed journals including papers in Cell, Cell Metabolism, Nature Reviews MCB, Nature Neuroscience, Nature Ageing, and Nature Biomedical Engineering. He has received several awards including the Butler-Williams Scholar on Aging 2016 by NIA (USA) and the ‘Scientific Award to Young Scientist in the Natural Sciences for 2020 by The Royal Norwegian Society of Sciences and Letters (Norway). He is the founding (co)coordinator of the Norwegian Centre on Healthy Ageing network (NO-Age, www.noage100.com), the Norwegian National anti-Alzheimer’s disease Network (NO-AD, www.noad100.com), and the Hong Kong-Nordic Research Network.

Funded Research

These projects were made possible from Cure Alzheimer's Fund support.

Project Description Researchers Funding
Turning Up Mitophagy to Blunt Alzheimer’s Tau Pathologies 2022